Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546 Campbell, 2006, The myeloproliferative disorders., N Engl J Med, 355, 2452, 10.1056/NEJMra063728 Kiladjian, 2006, Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders., Leukemia, 20, 1181, 10.1038/sj.leu.2404214 Pikman, 2006, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia., PLoS Med, 3, e270, 10.1371/journal.pmed.0030270 Klampfl, 2013, Somatic mutations of calreticulin in myeloproliferative neoplasms., N Engl J Med, 369, 2379, 10.1056/NEJMoa1311347 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2., N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Tefferi, 2014, An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms., Leukemia, 28, 1407, 10.1038/leu.2014.35 Kiladjian, 2008, The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases., Blood, 111, 4922, 10.1182/blood-2007-11-125328 Tefferi, 2015, New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera., Am J Hematol, 90, 683, 10.1002/ajh.24037 Vannucchi, 2015, A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis., Haematologica, 100, 1139, 10.3324/haematol.2014.119545 Silver, 1993, Interferon-alpha 2b: a new treatment for polycythemia vera., Ann Intern Med, 119, 1091, 10.7326/0003-4819-119-11-199312010-00006 Kiladjian, 2006, High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a., Blood, 108, 2037, 10.1182/blood-2006-03-009860 Quintás-Cardama, 2009, Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera., J Clin Oncol, 27, 5418, 10.1200/JCO.2009.23.6075 Kiladjian, 2011, The renaissance of interferon therapy for the treatment of myeloid malignancies., Blood, 117, 4706, 10.1182/blood-2010-08-258772 Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera., Blood, 112, 3065, 10.1182/blood-2008-03-143537 Vainchenker, 2011, New mutations and pathogenesis of myeloproliferative neoplasms., Blood, 118, 1723, 10.1182/blood-2011-02-292102 Shih, 2012, The role of mutations in epigenetic regulators in myeloid malignancies., Nat Rev Cancer, 12, 599, 10.1038/nrc3343 Schaub, 2010, Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms., Blood, 115, 2003, 10.1182/blood-2009-09-245381 Delhommeau, 2009, Mutation in TET2 in myeloid cancers., N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069 Lundberg, 2014, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms., Blood, 123, 2220, 10.1182/blood-2013-11-537167 Vannucchi, 2013, Mutations and prognosis in primary myelofibrosis., Leukemia, 27, 1861, 10.1038/leu.2013.119 Guglielmelli, 2014, The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients., Leukemia, 28, 1804, 10.1038/leu.2014.76 Harutyunyan, 2011, p53 lesions in leukemic transformation., N Engl J Med, 364, 488, 10.1056/NEJMc1012718 Rampal, 2014, Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms., Proc Natl Acad Sci USA, 111, E5401, 10.1073/pnas.1407792111 Tefferi, 2014, CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients., Leukemia, 28, 1494, 10.1038/leu.2014.57 Kiladjian, 2010, Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells., Leukemia, 24, 1519, 10.1038/leu.2010.120 Cassinat, 2014, Interferon alfa therapy in CALR-mutated essential thrombocythemia., N Engl J Med, 371, 188, 10.1056/NEJMc1401255 Barbui, 2011, Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet., J Clin Oncol, 29, 761, 10.1200/JCO.2010.31.8436 Barosi, 2009, Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference., Blood, 113, 4829, 10.1182/blood-2008-09-176818 Yue, 2012, Hepatitis B virus-induced calreticulin protein is involved in IFN resistance., J Immunol, 189, 279, 10.4049/jimmunol.1103405 Guglielmelli, Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis [published online ahead of print August 25, 2015]., Br J Haematol Baerlocher, 2015, Telomerase inhibitor imetelstat in patients with essential thrombocythemia., N Engl J Med, 373, 920, 10.1056/NEJMoa1503479 Tefferi, 2015, A pilot study of the telomerase inhibitor imetelstat for myelofibrosis., N Engl J Med, 373, 908, 10.1056/NEJMoa1310523 Rumi, 2014, Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis., Blood, 124, 1062, 10.1182/blood-2014-05-578435 Quintás-Cardama, 2013, Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a., Blood, 122, 893, 10.1182/blood-2012-07-442012 Patel, 2015, Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib., Blood, 126, 790, 10.1182/blood-2015-03-633404 Marty, 2013, A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression., Leukemia, 27, 2187, 10.1038/leu.2013.102 Busque, 2012, Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis., Nat Genet, 44, 1179, 10.1038/ng.2413 Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies., Nat Med, 20, 1472, 10.1038/nm.3733 Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes., N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617 Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence., N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405